Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 16c
Tweet
Share
E-mailGet Alerts ADAP Hot Sheet
Join SI Premium – FREE
Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of ($0.05), $0.16 better than the analyst estimate of ($0.21).
For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- Evercore ISI on Jersey Mike's Subs (JMKE): 'Anticipating a positive outlook'
- TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
